Drug intelligence / Profile preview

L-655

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral, Topical, Transdermal, Buccal, Sublingual, Transmucosal, Wound Dressing, Inhalation, Insufflation, Intraperitoneal, Intracerebral

Overview

L-655 is a DP1-specific antagonist that has been studied in experimental murine models of atherosclerosis. In these studies, L-655 generally had a neutral to beneficial effect on aortic lipids, both with and without nicotinic acid treatment. It did not negate the beneficial effects of nicotinic acid, which is used to treat dyslipidemia. The drug targets the DP1 receptor, which is involved in the flushing response mediated by prostaglandin D2.

Targets

GABRA5 (Gamma-aminobutyric acid type A receptor subunit alpha-5)

Beyond the preview

Go deeper on L-655.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L-655.

Explore the full profile